Merck to acquire San Diego biotech company Prometheus Biosciences for $10.8 billion
Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.
Source link
Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.
Source link
PHILADEPHIA, PA 19134
(267) 507-5453
mail@sellourhousephilly.com
We are a real estate solutions and investment firm that specializes in helping homeowners get rid of trouble houses fast. We are investors and problem solvers who can buy your house fast with a fair all cash offer. We’ll know very quickly if we can help you, and unlike selling through an agent, you don’t have to wait to see if the buyer can get financing… we’re ready to buy right now!